ストックスクリーナーアプリを入手
1.10
2.65%
-0.03
アフターアワーズ：
1.10
前日終値:
$1.13
開ける：
$1.12
24時間の取引高:
26,412
Relative Volume:
0.12
時価総額：
$5.26M
収益：
$19.53M
当期純損益:
$-3.18M
株価収益率:
-0.5826
EPS:
-1.888
ネットキャッシュフロー:
$-4.13M
1週間 パフォーマンス:
-3.51%
1か月 パフォーマンス:
-10.57%
6か月 パフォーマンス:
-66.46%
1年 パフォーマンス:
-63.09%
1日の値動き範囲:
$1.10
$1.14
1週間の範囲:
$1.10
$1.21
52週間の値動き範囲:
$0.8501
$6.9199
Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile
名前
Sonoma Pharmaceuticals Inc
セクター
電話
800-759-9305
住所
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Compare SNOA vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
1.10 | 5.50M | 19.53M | -3.18M | -4.13M | -1.888 |
TAK
Takeda Pharmaceutical Co Adr
|
17.10 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.855 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.01 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.28 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.71 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Sonoma Pharmaceuticals Inc (SNOA) 最新ニュース
Sonoma Pharmaceuticals Inc (SNOA) Institutional Confidence - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sonoma Pharmaceuticals Inc - TradingKey
SNOA|Sonoma Pharmaceuticals Inc|Price:1.140|Chg%:-0.020 - TradingKey
TradingKey - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
19,898 Common Stock of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 24-JUL-2026. - marketscreener.com
Sonoma Pharmaceuticals (SNOA) Edges Higher as Volume Patterns Suggest Accumulation Near Key SupportAAII Bearish - dars.gov.et
Sonoma Pharmaceuticals (SNOA) Slips 4.21% as Stock Tests Key Support LevelsNAAIM Leverage - dars.gov.et
Sonoma Pharmaceuticals (SNOA) Holds Steady at $1.26 as Consolidation ContinuesInside Day Breakout - dars.gov.et
Enterprise value to revenue forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Form 4 Sonoma Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Price to sales forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Sonoma Pharmaceuticals (NASDAQ: SNOA) awards CEO 10,000 RSUs in equity grant - Stock Titan
Enterprise value to EBIT forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Price to book forward of Sonoma Pharmaceuticals, Inc. – FWB:O8Z - TradingView
Price to sales forward of Sonoma Pharmaceuticals, Inc. – FWB:O8Z - TradingView
SNOA Should I Buy - Intellectia AI
Sonoma Pharmaceuticals (SNOA) Secures FDA Clearance for Microdac - GuruFocus
Sonoma Pharmaceuticals receives FDA clearance for wound solution - Investing.com
Sonoma Pharmaceuticals receives FDA clearance for wound solution By Investing.com - Investing.com Canada
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution - ACCESS Newswire
Sonoma Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SNOA) - TradingView
Sonoma Pharmaceuticals Inc (SNOA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity - The Globe and Mail
Sonoma Pharmaceuticals Files 8-K for $3.6 Million Common Stock Offering – Nasdaq: SNOA, June 2026 - Minichart
According to a recent filing submitted to the U.S. Securities and Exchange Commission (SEC), Sonoma Pharmaceuticals, Inc. has raised the maximum total offering price of its common stock issuance to $3.64 million. - Bitget
Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million - Investing.com UK
Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million By Investing.com - Investing.com Nigeria
Sonoma Pharmaceuticals boosts shelf offering capacity to $3.64M after prior $574.6K sales - TradingView
[8-K] Sonoma Pharmaceuticals, Inc. Reports Material Event - Stock Titan
Sonoma Pharmaceuticals Inc (SNOA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sonoma Pharmaceuticals Q4 revenue rises 48% on US growth - TradingView
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results - ACCESS Newswire
BRIEF-Sonoma Pharmaceuticals Q4 Net Income USD -600 Thousand - TradingView
Sonoma Pharmaceuticals, Inc. FY 2026: Revenue $19.5M, EPS $(1.89) — 10-K Summary - TradingView
Sonoma Pharmaceuticals | 10-K: FY2026 Annual Report - Moomoo
Sonoma Pharmaceuticals (NASDAQ: SNOA) outlines global HOCl strategy and risks - Stock Titan
SNOA Q1 2026 Earnings: EPS Misses Estimates Amid Operational and Revenue Disclosures - newsline.com
Sonoma Pharmaceuticals Q1 2026 Earnings: EPS Miss Triggers Sharp SelloffCFO Commentary Report - newsline.com
Sonoma Pharmaceuticals Inc. (SNOA) Q1 2026 Earnings: EPS Falls Short of Estimates, Stock Unchanged - newsline.com
Sonoma Pharmaceuticals (SNOA) Edges Higher, Holds Within Established Trading RangeAAII Bearish - dars.gov.et
SNOA Q1 2026 Earnings: EPS Misses Estimates, Stock Rises 2.7%Dividend Cut Risk - dars.gov.et
SNOASonoma Pharmaceuticals Inc Stock Price and Quote - Finviz
Sonoma Pharmaceuticals (SNOA) Edges Higher, Testing Resistance at $1.13Channel Breakout - The Legal Advocate
Sonoma Pharmaceuticals Inc. (SNOA) Q1 2026 Earnings: EPS Slightly Misses Estimates Amid Thin Revenue DisclosuresOne-Time Gain Impact - newsline.com
Sonoma Pharmaceuticals (SNOA) Edges Higher, Testing Key Resistance at $1.13Volatility Smirk - Newser
Sonoma Pharmaceuticals Inc (SNOA) 財務データ
収益
当期純利益
現金流量
EPS
2.08%
0.17%
大文字化:
|
ボリューム (24 時間):